



University of Dundee

Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis'

Affleck, A.; Goudie, A.; Smith, R.

Published in:
Clinical and Experimental Dermatology

DOI:
[10.1111/ced.13993](https://doi.org/10.1111/ced.13993)

Publication date:
2019

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Affleck, A., Goudie, A., & Smith, R. (2019). Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis': reply from author. *Clinical and Experimental Dermatology*, 44(5), 593-594. <https://doi.org/10.1111/ced.13993>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Article Type: Correspondence

Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis': reply from author

A. Affleck,¹ A. Goudie² and R. Smith²

Departments of ¹Dermatology and ²Respiratory Medicine, Ninewells Hospital,
Dundee, UK

Corresponding author: Andrew Affleck

E-mail: andrew.affleck@nhs.net

ORCID: 0000-0002-0385-3186

Funding: None

Conflicts of interest: None to declare

Thank you for your interest in our case report.¹ We did state that the cause of death was *idiopathic* pulmonary fibrosis (IPF) due to typical clinical and radiological findings. We agree that there appears to be some overlap in pathogenetic

This is the peer reviewed version of the following article: Affleck, A., et al. "Comment on 'Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis'", *Clinical and Experimental Dermatology* (2019), which has been published in final form at <https://doi.org/10.1111/ced.13993>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

This article is protected by copyright. All rights reserved.

Accepted Article

mechanisms between psoriasis and IPF e.g. raised IL-17; indeed, the possibility of a restrictive form of psoriatic lung disease has been raised although it appears to be rare. Significantly, both cutaneous psoriasis and pulmonary changes can improve with anti-interleukin (IL) 12/IL-23 or IL-17 antibodies.² A recent study reported that patients with psoriasis may be at increased risk of developing interstitial lung disease (most commonly IPF) independent of previous or concomitant exposure to immunosuppressants.³ We agree that *theoretically*, low blood folate levels could be a risk for developing pneumonitis or potentially a chronic interstitial pneumonia exacerbated by methotrexate. However, as is standard clinical practice, our patient had folic acid 5mg daily throughout his methotrexate therapy and given the elapsed time on therapy he did not have a pneumonitis. We do not believe that there is sufficient evidence to suggest higher daily doses of folic acid for patients having methotrexate for psoriasis. Methotrexate-induced pneumonitis appears to be idiosyncratic and so preventative measures are not likely to be helpful for the vast majority of patients. The remote possibility of an interstitial lung disease (ILD) associated with psoriasis does not justify routine radiological screening and biomarkers, although desirable, e.g. serum KL-6, are not reliable or validated for use in clinical practice. We do advocate the general measure of cessation of cigarette smoking in all patients with psoriasis whether or not they are on systemic therapy as this may reduce the chance of developing an ILD such as IPF or separately COPD (another recently proposed extracutaneous manifestation of psoriasis). Further research may help clarify this important and complex topic; we wonder whether the BADBIR large prospective database could shed light on the incidence of ILD in patients with moderate to severe psoriasis?

References

1. Abdelmaksoud A. Comment on "Fatal, incidental, idiopathic pulmonary fibrosis in a patient receiving long-term low-dose methotrexate for psoriasis". *Clin Exp Dermatol* 2019 Apr 3. doi: 10.1111/ced.13975. [Epub ahead of print]
2. Ishikawa G, Acquah S, Salvatore M, Padilla ML. Interstitial Lung Disease With Psoriasis. *Am J Respir Crit Care Med* 2017; **195**: A7122.
3. Kawamoto H, Hara H, Minagawa S, Numata T *et al.* Interstitial Pneumonia in Psoriasis. *May Clin Proc Innov Qual Outcomes* 2018; **2**: 370-377.